The Research Antibodies and Reagents Market, valued at $4.08 billion in 2023, is set to expand to $6.77 billion by 2031. The market is projected to reach $4.36 billion in 2024, with a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031. This growth is attributed to the increasing use of biomarkers in targeted therapies, which allow for precise predictions of clinical outcomes across different populations and treatments.
Biomarkers, which are measurable indicators of disease severity, are becoming increasingly important in the medical field. Their significance is amplified by the need for selective therapies and the rising prevalence of chronic diseases, especially among aging populations. The demand for new biomarker identification is driven by the quest for more effective treatments, reduced clinical trial costs, and the growing incidence of chronic conditions.
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5055
Data from the United Nations and the World Bank highlight a significant demographic shift: the global population aged 60 and above increased from 566.9 million in 2013 to 673.6 million in 2018. This trend is expected to continue, with the number of individuals aged 80 and older projected to nearly triple by 2050, from 143 million to 426 million. By 2050, the number of people aged 60 and above in developing regions is expected to more than double, rising from 652 million to 1.7 billion. This aging population is likely to lead to an increase in chronic diseases, such as cancer.
Cancer incidence has surged dramatically in recent years. In 2012, there were about 14.1 million new cancer cases globally, which increased by approximately 28% to 18.1 million by 2018, according to GLOBOCAN. The number of new cases is projected to rise by 109.5% to 29.5 million by 2040. Cancer-related mortality also saw an increase, from 8.2 million deaths in 2012 to 9.6 million in 2018. Projections suggest that cancer mortality will grow by 58.5% to 13 million deaths by 2030 and by 100% to 16.4 million by 2040. This rising incidence and mortality of cancer is fueling the demand for targeted therapies, including antibodies, which is expected to drive growth in the research antibodies and reagents market.
In emerging economies, particularly in Latin America, cancer incidence continues to rise. In 2018, the region recorded 1.4 million new cancer cases, a number anticipated to grow by 40.1% to 1.98 million by 2030, and potentially reach 2.52 million cases by 2040. Similarly, cancer-related deaths in the region are expected to nearly double, from 672,758 in 2018 to 1.3 million by 2040. This increase in cancer prevalence is driving greater investment in drug discovery and development, as well as a heightened demand for targeted medicines.
Browse in Depth : https://www.meticulousresearch.com/product/research-antibodies-and-reagents-market-5055
Developing regions are also seeing increased investment in healthcare infrastructure, which is expected to further boost the demand for antibodies and related reagents. In India, the healthcare sector is expanding rapidly, supported by both public and private investment. The Indian Brand Equity Foundation (IBEF) notes that India is a major global provider of antiretroviral drugs, with over 3,500 hospitals and 25,000 dispensaries. Similarly, China’s 13th Five-Year Plan, initiated in 2016, aimed to enhance healthcare services and expand access to comprehensive care in both urban and rural areas. Brazil’s 2015 federal law changes have opened doors to foreign investment in healthcare, boosting funding for infrastructure in the region.
Advancements in biomarker discovery are also driving growth in the antibodies market. For example, protein array technology, which utilizes antibodies, was used for biomarker discovery in lupus as reported in the Proteomics Clinical Applications journal. Antibody-based assays have been employed to identify oral cancer biomarkers in saliva, as documented by the Oral Cancer Foundation. Furthermore, the Royal College of Surgeons in Ireland discovered blood biomarkers in drug-free schizophrenia patients using multiplex and proteomics immunoassays. New methods like whole auto-antibody mapping have emerged, facilitating scalable biomarker discovery in autoimmune diseases. These advancements are leading to the development of biomarker-based cancer diagnostics and therapies, such as HER2-targeted therapy for breast cancer through immunohistochemistry.
The growing use of immunohistochemistry and immunoassays for biomarker identification has increased the adoption of research antibodies, creating significant opportunities for market vendors. According to Meticulous Research, the global research antibodies and reagents market is projected to grow at a CAGR of 5.6%, reaching $6.32 billion by 2027.
Quick Buy: https://www.meticulousresearch.com/Checkout/11998366
About Meticulous Research®
Meticulous Research® is a leading provider of comprehensive market intelligence, offering actionable insights and analysis across various industries. Our reports empower businesses to make informed decisions, drive growth, and remain competitive in a rapidly evolving marketplace.
Contact:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
0 comment